JP7853096B2 - 抗体ライブラリー及び方法 - Google Patents

抗体ライブラリー及び方法

Info

Publication number
JP7853096B2
JP7853096B2 JP2021519644A JP2021519644A JP7853096B2 JP 7853096 B2 JP7853096 B2 JP 7853096B2 JP 2021519644 A JP2021519644 A JP 2021519644A JP 2021519644 A JP2021519644 A JP 2021519644A JP 7853096 B2 JP7853096 B2 JP 7853096B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
variant
trastuzumab
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021519644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512650A (ja
JP2022512650A5 (cg-RX-API-DMAC7.html
Inventor
リチャード ビュイック,
クリストファー スコット,
ダラッグ マッキャン,
レオナ マクギアー,
ヒュー モーガン,
ナターシャ キャンベル,
ジェームズ マクローリー,
アンソニー オケイン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Antibodies Ltd
Original Assignee
Fusion Antibodies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1817188.4A external-priority patent/GB201817188D0/en
Priority claimed from GBGB1904754.7A external-priority patent/GB201904754D0/en
Priority claimed from GBGB1905032.7A external-priority patent/GB201905032D0/en
Application filed by Fusion Antibodies Ltd filed Critical Fusion Antibodies Ltd
Publication of JP2022512650A publication Critical patent/JP2022512650A/ja
Priority to JP2025167548A priority Critical patent/JP2026016427A/ja
Publication of JP2022512650A5 publication Critical patent/JP2022512650A5/ja
Application granted granted Critical
Publication of JP7853096B2 publication Critical patent/JP7853096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021519644A 2018-10-22 2019-10-22 抗体ライブラリー及び方法 Active JP7853096B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025167548A JP2026016427A (ja) 2018-10-22 2025-10-03 抗体ライブラリー及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1817188.4 2018-10-22
GBGB1817188.4A GB201817188D0 (en) 2018-10-22 2018-10-22 Antibody library
GB1904754.7 2019-04-04
GBGB1904754.7A GB201904754D0 (en) 2019-04-04 2019-04-04 Antibody library and method
GBGB1905032.7A GB201905032D0 (en) 2019-04-09 2019-04-09 Antibody library and method
GB1905032.7 2019-04-09
PCT/GB2019/053010 WO2020084298A1 (en) 2018-10-22 2019-10-22 Antibody library and method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025167548A Division JP2026016427A (ja) 2018-10-22 2025-10-03 抗体ライブラリー及び方法

Publications (3)

Publication Number Publication Date
JP2022512650A JP2022512650A (ja) 2022-02-07
JP2022512650A5 JP2022512650A5 (cg-RX-API-DMAC7.html) 2025-10-30
JP7853096B2 true JP7853096B2 (ja) 2026-04-28

Family

ID=68393020

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519644A Active JP7853096B2 (ja) 2018-10-22 2019-10-22 抗体ライブラリー及び方法
JP2025167548A Pending JP2026016427A (ja) 2018-10-22 2025-10-03 抗体ライブラリー及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025167548A Pending JP2026016427A (ja) 2018-10-22 2025-10-03 抗体ライブラリー及び方法

Country Status (10)

Country Link
US (2) US12378696B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870607A1 (cg-RX-API-DMAC7.html)
JP (2) JP7853096B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210084509A (cg-RX-API-DMAC7.html)
CN (1) CN113195537A (cg-RX-API-DMAC7.html)
AU (1) AU2019365135B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007529A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115150A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004149A (cg-RX-API-DMAC7.html)
WO (1) WO2020084298A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7473339B2 (ja) * 2017-03-07 2024-04-23 エフ. ホフマン-ラ ロシュ アーゲー 代替の抗原特異的抗体変異体を発見するための方法
CN112289369B (zh) * 2020-12-15 2021-04-02 武汉华美生物工程有限公司 一种基于深度学习的抗体库构建方法及装置
CN114775065B (zh) * 2022-04-22 2026-01-06 武汉华美生物工程有限公司 一种半合成纳米抗体库构建方法和纳米抗体库
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途
CN121737857A (zh) * 2024-09-26 2026-03-27 上海循曜生物科技有限公司 增强FIX和FIXa活性的纳米抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073346A1 (en) 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016188911A1 (en) * 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
CN109576292B (zh) * 2018-12-21 2022-11-29 深圳市爱思迪生物科技有限公司 一种抗体文库的构建方法及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073346A1 (en) 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bostrom J. et al.,Science,2009年,Vol. 323,pp.1610-1614, Supporting Online Material
Halemano K. et al.,Proc Natl Acad Sci U S A,Vol. 111,2014年,pp. 7759-7764
Muller BH. et al.,J Mol Biol,2011年,Vol. 414,pp. 545-562
Su YC. et al.,mAbs,2014年,Vol. 6,pp. 1069-1083

Also Published As

Publication number Publication date
WO2020084298A1 (en) 2020-04-30
US12378696B2 (en) 2025-08-05
JP2022512650A (ja) 2022-02-07
CN113195537A (zh) 2021-07-30
US20210388063A1 (en) 2021-12-16
KR20210084509A (ko) 2021-07-07
BR112021007529A2 (pt) 2021-08-03
AU2019365135A1 (en) 2021-05-13
JP2026016427A (ja) 2026-02-03
US20250382726A1 (en) 2025-12-18
AU2019365135B2 (en) 2026-08-13
MX2021004149A (es) 2021-06-15
EP3870607A1 (en) 2021-09-01
CA3115150A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US10562982B2 (en) Methods for producing Fabs and bi-specific antibodies
US20250382726A1 (en) Antibody Library and Method
JP6856610B2 (ja) ヘテロ二量体免疫グロブリンの精製
Traxlmayr et al. Construction of a stability landscape of the CH3 domain of human IgG1 by combining directed evolution with high throughput sequencing
US20190292268A1 (en) Methods for Producing Fabs and IgG Bispecific Antibodies
CA2922979A1 (en) Readily isolated bispecific binding molecules with native format having mutated constant regions
TW201925232A (zh) 與集落刺激因子1受體(csf1r)結合之抗體類
AU2017428737A1 (en) Dynamic human heavy chain antibody libraries
JP2026508171A (ja) 共通軽鎖抗体ライブラリーとその調製方法及び用途
TW202222824A (zh) Egfr結合複合物及其製備和使用方法
JP2023106414A (ja) 真核宿主細胞において多量体タンパク質を産生する方法
AU2010322202B2 (en) Display of disulfide linked dimeric proteins on filamentous phage
WO2024006975A1 (en) Methods for antibody humanization
WO2011131659A2 (en) Binding domains
US20110245100A1 (en) Generation of antibodies to an epitope of interest
CN119855835A (zh) 基于共同轻链产生双特异性抗体的方法
WO2026059472A1 (en) Bivalent bispecific antibody and method for producing thereof
KR20230015957A (ko) 이중특이적 항체 및 이의 용도
KR20220087488A (ko) Pd-l1 결합 분자

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250603

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20251003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260416

R150 Certificate of patent or registration of utility model

Ref document number: 7853096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150